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1 , Lars-Jörgen Hansson 1 , Gunnel Bynke 1 and Albert N. Békássy C ytomegalovirus (CMV) retinitis is an infection affecting up to one third of patients (range 5.7-37%) with acquired immunodeficiency syndrome (AIDS; Jacobson et al. 1988; Jabs 1995) . A selective T-cell dysfunction, more specifically a low CD4 T lymphocyte count predispose AIDS patients to the infection (Pertel et al. 1992) . In other immunosuppressed patient categories, the incidence of CMV retinitis is comparatively low. One such category is represented by leukemia patients treated with stem cell transplantation (SCT). These patients undergo a conditioning regimen before the infusion of bone marrow to deplete the recipient's bone marrow, thereby allowing repopulation of the bone marrow with donor cells, and minimizing the risk of graft rejection. Additionally, these patients are kept on immunosuppressive therapy postoperatively to prevent the much feared complication of graft-versus-host disease (GvHD). As a consequence of the immunosuppression, CMV infections after SCT are quite common and affects various organs (Guyotat et al. 1987) , but CMV retinitis has been reported only sporadically (Kaulfersch et al. 1989; McAuliffe et al. 1997) . We here report the successful treatment of a 16-year-old patient, suffering from bilateral CMV retinitis following SCT.
Case Report
The patient was diagnosed with acute lymphoblastic leukemia at the age of five. He was treated according to Swedish Children Leukemia Group protocol with intense combined chemotherapy for 3 years. Remission was induced, but two relapses occurred subsequently at 11 and 14 years of age. While in his third remission, induced by chemotherapy, he received an allogeneic stem cell graft from an unrelated bone marrow donor at the age of 16. The preparative regimen included total body irradiation and chemotherapy (high-dose Ara-C and cyclophosphamide). He made an uneventful hematological recovery and was managed on ciklosporine-A, as a GvHD prophylaxis.
CMV reactivation occurred five weeks post grafting, verified by quantitative PCR in the broncho-alveolar lavage and body excretes. Serious and rapidly progressing pneumonia was diagnosed on chest X-ray within a week. A routine eye examination at this time revealed 1.0 (Monoyer) visual acuity (VA) in both eyes and a normal fundus appearance. In spite of aggressive antiviral intravenous treatment with immunoglobulin and ganciclovir for four weeks, the condition of the pa- tient deteriorated, and he became oxygen dependent. Ciclosporine-A immunosuppression was discontinued three months after transplantation with no occurrence of GvHD. Thoracoscopic lung biopsy one month later showed a morphology of heavy viral pneumonia resembling obliterative bronchiolitis. The cause was identified by immunohistochemistry as a coinfection of CMV and Influenza A virus.
The patient now started to complain of dim vision and VA had fallen to 0.4 in both eyes. CMV retinitis was diagnosed, with both eyes displaying multiple whitish retinal infiltrates and hemorrhages as well as low grade macular edema. Treatment was intensified to include both ganciclovir and foscarnet intravenously, but the retinitis progressed with more infiltrates, hemorrhages and increasing exudative lesions in both maculae. To save the retinae, intravitreal injections of ganciclovir according to the protocol developed by Young et al. (1998) was started in both eyes, five months after the stem cell transplant. The patient was completely immune depleted at this time judged by CD4 count 0.08 ¿ 10E9/L (normal value is 0.5-1.6 ¿ 10E9/L) and markedly low T cell reactivity measured by phytohemagglutinin (PHA) stimulation test. The deteriorating state of the patient and the need for general anesthesia to perform the procedure, made planning of the required weekly intravitreal injections difficult. Instead a sustained-release ganciclovir device was implanted in each eye.
The implantation procedure was, with a few exceptions, identical to the one described by Sanborn et al. (1992) . The patient was put under general anesthesia. The ganciclovir containing device (Vitrasert A , Bausch & Lomb Surgical Inc., Claremont, California, USA) was prepared by trimming the anchoring strut and passing a double armed 9-0 nylon suture through the base. A conjunctival peritomy was performed in the lower temporal quadrant and a 5-mm limbus parallel sclerotomy was made 4 mm from the limbus with a microvitreoretinal blade. The device was now grasped with smooth forceps and introduced into the vitreous cavity. The anchoring suture was passed through either side of the scleral incision and tied. Additional 9-0 nylon sutures were placed to close the wound and the conjunctiva was closed with 8-0 vicryl sutures. Bethametasone and gentamicin were injected subconjunctivally. An indirect fundus examination was performed confirming the proper position of the implants. No peroperative complications were noted.
Five days after implantation the fundus appeared unchanged from preoperative examination and the patient had a VA of 0.04 RE and 0.3 LE (Figs 1A and  B) . The pathological findings in the fundus subsequently diminished, and the visual acuity 19 days postoperatively was 0.7 in both eyes. Two months after surgery, the VA was 0.6 RE, and 0.9 LE (Figs 1C  and D) . Most hemorrhages and all infiltrates had disappeared at this time, but exudative lesions were still present in both maculae (Figs 1C and D) . Six months after implantation (11 months after the SCT), the VA was 1.0 in both eyes, and no macular edema, infiltrates or hemorrhages could be seen (Figs 1E and F) . Minimal retinal atrophies could be detected in the right eye as the only remaining sign of the CMV retinitis. At no time did the patient report any discomfort locally or visual field disturbances from the implants.
The general condition of the patient, i.e. his lung capacity, gradually improved seven months after the stem cell transplantation (SCT) and oxygen requirement was discontinued. He was, however, kept on systemic intense combined antiviral therapy. By this time, CMV quantitative PCR analysis of the body excretes showed weak positive reaction, but gene sequencing of the CMV isolate verified ganciclovir-resistant C607Y genotypic mutation. As clinical improvement and immune recovery was already evident (by reoccurrence of PHA tested T-cell reactivity and CD4 count reaching the so called 'magical' 0.2 ¿ 109/L limit), all systemic antiviral treatment was stopped. At follow up, 11 months after the SCT, the general condition of the patient was completely restored. Immunological screening showed CD4 count at the lower limit of the normal range and PHA-induced Tcell stimulatory response was normal.
Discussion
The introduction of ganciclovir and foscarnet has radically changed the poor prognosis of CMV retinitis. One of the more recent additions to the armamentarium of treatments is the sustained-release intravitreal ganciclovir implant which has been successfully used in AIDS patients (Sanborn et al. 1992; Martin et al. 1994) . Reported complications of the operation include endophthalmitis, extrusion of the implant, retinal detachment, vitreous hemorrhage and placement of the implant in the suprachoroidal space (Sanborn et al. 1992; Anand et al. 1993) . We found the implant procedure fairly simple to perform, and did not experience any per-or postoperative complications during the six-month follow-up in the patient reported here.
Intravitreal administration of ganciclovir is a treatment for CMV retinitis only, and cannot be given as single therapy when systemic infection is present. On the other hand intravitreal ganciclovir is more efficient in treating CMV retinitis than intravenous (i.v.) administration of the drug (Young et al. 1998) , which is well illustrated in our patient who received both foscarnet and ganciclovir i.v., but still progressed in his retinitis. Additionally, local ganciclovir therapy minimizes the hazardous side-effects of i.v. ganciclovir (bone marrow suppression) and foscarnet (nephrotoxicity), and has shown very little, if any, adverse effects on the ocular tissues (Charles & Steiner 1996; Young et al. 1998) . The sustained-release device remains active for six to seven months, after which time it can be replaced or supplemented by a second device at a different operation site if sustained therapy is required (Morley et al. 1995) .
Reports on the implant being used in patients suffering from CMV retinitis after bone marrow transplant are few and include only the adult population (McAuliffe et al. 1997 ). To our knowledge the present case represents the first pediatric patient treated with the ganciclovir implant after stem cell transplantation.
Cytomegalovirus infection in the immunosuppressed patient represents a reactivation of a latent primary infection. When and if immune competence is regained, the virus is controlled and the CMV virus returns to its previously latent stage. A reconstitution of the immune system is thus of utmost importance in any immunosuppressed patient displaying signs of active CMV infection.
Our patient was CMV positive at the time of his stem cell transplant but the donor was not. As a consequence, no immunologic memory was established in the donor immune system and the CMV infection was reactivated since the patients own immune cells were obliterated by the conditioning and postgrafting immunosuppressive treatment. The very slow reconstitution of the immune system in spite of the early discontinuation of im-munosuppressive therapy allowed the CMV to ravage systemically, in the lungs and retinae. Antiviral therapy under such conditions is directed at stopping the progress of the disease until immunological reconstitution is achieved. The rapid improvement of the CMV retinitis of our patient suggests that the intravitreal ganciclovir implant controlled the CMV retinitis directly, but the long duration of the sustained-release preparation also gave the patient enough time to reconstitute his new immune system, without irreversible damage to the retina.
To summarize, we have illustrated that the intravitreal sustained-release ganciclovir device can be effective in treating CMV retinitis in a severely immunosuppressed patient. We suggest that the device should be considered not only in adult patients suffering from AIDS but also in young patients with CMV retinitis after stem cell transplantation.
